Patents Assigned to The Zhabilov Trust
  • Irreversibly-inactivated pepsinogen fragments for modulating immune function
    Patent number: 8309072
    Abstract: Isolated anti-cancer peptides are disclosed which are characterized by the amino acid sequences TLTSGGGAIALPPSMAAPPLGPVAPLTGAIHAPTXG (SEQ ID NO: 1); TLSTATGGAIPPVAAMPPGLVAPTHGPAIHP (SEQ ID NO: 2); CCATSGPCGAVMILTPHLTA (SEQ ID NO: 5); MTLTTGSGAIAPAMPPGLPPHTGAIHAPM (SEQ ID NO: 4); and NXVPVSVEGYXQITLDSITX (SEQ ID NO: 3) and a significant in vitro binding affinity for gp96. The peptides exhibit anti-tumor, anti-cancer activity in vivo. Also disclosed is an isolated antiviral peptide characterized by the amino acid sequence GDEPLENYLDTEYF (SEQ ID NO: 6) and a significant in vitro binding affinity for HIV-1 gp 120 and gp 41, and human CD4 cells. The peptide exhibits anti-retroviral activity in vivo, particularly anti-HIV-1 activity.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: November 13, 2012
    Assignee: The Zhabilov Trust
    Inventor: Harry H. Zhabilov
  • Inactivated pepsin fragments for modulating immune system activity against human malignant tumor cells
    Patent number: 8067531
    Abstract: Isolated anti-cancer peptides are disclosed which are characterized by the amino acid sequences TLTSGGGAIALPPSMAAPPLGPVAPLTGAIHAPTXG; TLSTATGGAIPPVAAMPPGLVAPTHGPAIHP; CCATSGPCGAVMILTPHLTA; MTLTTGSGAIAPAMPPGLPPHTGAIHAPM; and NXVPVSVEGYXQITLDSITX and a significant in vitro binding affinity for gp96. The peptides exhibit anti-tumor, anti-cancer activity in vivo. Also disclosed is an isolated antiviral peptide is characterized by the amino acid sequence GDEPLENYLDTEYF and a significant in vitro binding affinity for HIV-1 gp 120 and gp 41, and human CD4 cells. The peptide exhibits anti-retroviral activity in vivo, particularly anti-HIV-1 activity.
    Type: Grant
    Filed: December 2, 2008
    Date of Patent: November 29, 2011
    Assignee: The Zhabilov Trust
    Inventor: Harry H. Zhabilov
  • Irreversibly-inactivated pepsinogen fragment and pharmaceutical compositions comprising the same for detecting, preventing and treating HIV
    Patent number: 8066982
    Abstract: An isolated antiviral peptide is characterized by the amino acid sequence GDEPLENYLDTEYF and a significant in vitro binding affinity for HIV-1 gp 120 and gp 41 and human CD4 cells. The peptide exhibits anti-retroviral activity in vivo, particularly anti-HIV-1 activity.
    Type: Grant
    Filed: January 16, 2009
    Date of Patent: November 29, 2011
    Assignee: The Zhabilov Trust
    Inventor: Harry H. Zhabilov
  • Irreversibly-inactivated pepsinogen fragment and pharmaceutical compositions comprising the same for detecting, preventing, and treating HIV
    Patent number: 7479538
    Abstract: An isolated antiviral peptide is characterized by the amino acid sequence GDEPLENYLDTEYF and a significant in vitro binding affinity for HIV-1 gp 120 and gp 41, and human CD4 cells. The peptide exhibits anti-retroviral activity in vivo, particularly anti-HIV-1 activity.
    Type: Grant
    Filed: July 11, 2005
    Date of Patent: January 20, 2009
    Assignee: The Zhabilov Trust
    Inventor: Harry H. Zhabilov